Should site-neutral payment rules and policies be extended to commercial payers, payment for physician-administered drugs, and services delivered in on-campus hospital outpatient departments?
We want to know what you’re thinking! Every Tuesday morning, the editors of Managed Healthcare Executive are posing a question to our readers about a timely issue in U.S. healthcare. We'll tally your answers and publish the results on Friday by 4 p.m. ET.
Some background on this week’s question
Payment for outpatient services has traditionally varied depending on where the services were delivered. Typically, they have been higher at hospital outpatient facilities than at physician offices. But as hospitals have bought physician practices and expanded their outpatient facilities, payers and others have pushed for “site-neutral” payment that pays the same amount for the service, regardless of where it is delivered. Medicare already has some site-neutral payment policies.
Now Congress and regulators are considering legislation and rules that would extend site-neutral payment further to include physician-administered drugs and outpatient facilities located on hospital campuses. Some proposals would also apply site-neutral payment rules to commercial payers.
Hospitals and some other groups are fighting site-neutral payment, arguing that patients seen in hospital facilities receive more coordinated care and are often more medically complex.
Should site-neutral payment rules and policies be extended to commercial payers, payment for physician-administered drugs, and services delivered in on-campus hospital outpatient departments?
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
High-Dose Eylea Shows Unique Properties in nAMD and DME | AAO 2024
October 22nd 2024A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks to as long as 20 weeks for neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).
Read More
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen